The Most Common Misunderstanding about Compulsory Licensing
The belief that a country can only use compulsory licensing in cases of public health emergencies is a myth that has proven difficult to...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
The US NIH will share technology with WHO to fight the pandemic
The US National Institutes of Health today committed to sharing several technologies with a World Health Organization body tasked with increasing access to Covid-19...
“Mutually agreed terms and conditions,” says it all.
On 4 March, Politico reported that the Polish presidency of the Council of the European Union (EU) is expressing doubt that the Pandemic Agreement...
The Power of TRIPS Flexibilities in Medicines Procurement
The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV). Treatment will be a combination of...
The elephant in the room at the WHO Executive Board
The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...
Remdesivir developed country price announced
On 29, June 2020 Gilead announced its global price for developed countries for remdesivir, a medicine that has shown some effect in the treatment...
Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....
World Trade Organization Members Embark on Review of the TRIPS Agreement
The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review...
Human Rights Watch: All governments should endorse the WHO C-TAP Solidarity Call to Action
As the race towards a Covid-19 vaccine continues – with 11 leading candidates in phase 3 clinical trials, 14 more in phase 2 and...